Sangamo Therapeutics and Genentech enter a global licensing deal for intravenous genomic medicines for neurodegenerative disorders, including Alzheimer's.

Sangamo Therapeutics and Genentech have entered a global licensing deal to advance the development of intravenous genomic medicines for neurodegenerative disorders like Alzheimer's. Sangamo will grant Genentech exclusive rights to its zinc finger repressors targeting the tau gene and another undisclosed neurological target, along with its AAV capsid, STAC-BBB. Genentech will handle clinical development, regulatory affairs, manufacturing, and global commercialization, paying Sangamo $50m in upfront license fees and milestone payments, with the potential for Sangamo to earn up to $1.9bn in development and commercial milestones and tiered royalties.

August 06, 2024
4 Articles